Pretreatment SUVmax predicts progression-free survival in early-stage non-small cell lung cancer treated with stereotactic body radiation therapy

This retrospective study aims to assess the usefulness of SUV(max) from FDG-PET imaging as a prognosticator for primary biopsy-proven stage I NSCLC treated with SBRT. This study includes 95 patients of median age 77 years, with primary, biopsy-confirmed peripheral stage IA/IB NSCLC. All patients wer...

Full description

Saved in:
Bibliographic Details
Published in:Radiation oncology (London, England) England), 2014-01, Vol.9 (1), p.41-41, Article 41
Main Authors: Horne, Zachary D, Clump, David A, Vargo, John A, Shah, Samir, Beriwal, Sushil, Burton, Steven A, Quinn, Annette E, Schuchert, Matthew J, Landreneau, Rodney J, Christie, Neil A, Luketich, James D, Heron, Dwight E
Format: Article
Language:English
Subjects:
Aged
Aged, 80 and over
Cancer therapies
Carcinoma, Non-Small-Cell Lung - diagnostic imaging
Carcinoma, Non-Small-Cell Lung - metabolism
Carcinoma, Non-Small-Cell Lung - pathology
Carcinoma, Non-Small-Cell Lung - surgery
Care and treatment
Clinical trials
Development and progression
Diagnosis
Disease-Free Survival
Female
Fluorodeoxyglucose F18 - pharmacokinetics
Health aspects
Humans
Lung cancer
Lung cancer, Non-small cell
Lung Neoplasms - diagnostic imaging
Lung Neoplasms - metabolism
Lung Neoplasms - pathology
Lung Neoplasms - surgery
Male
Medical equipment and supplies industry
Medical imaging
Medical research
Medical test kit industry
Medicine, Experimental
Middle Aged
Multimodal Imaging
Neoplasm Staging
PET imaging
Positron-Emission Tomography - methods
Prognosis
Radiation
Radiation therapy
Radiosurgery
Radiotherapy
Radiotherapy Planning, Computer-Assisted - methods
Studies
Surgery
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This retrospective study aims to assess the usefulness of SUV(max) from FDG-PET imaging as a prognosticator for primary biopsy-proven stage I NSCLC treated with SBRT. This study includes 95 patients of median age 77 years, with primary, biopsy-confirmed peripheral stage IA/IB NSCLC. All patients were treated with 60 Gy in 3 fractions with a median treatment time of six days. Local, regional, and distant failures were evaluated independently according to the terms of RTOG1021. Local, regional, and distant control, overall- and progression-free survival were estimated by the Kaplan-Meier method. Cox proportional hazards regression was performed to determine whether SUV(max), age, KPS, gender, tumor size/T stage, or smoking history influenced outcomes. SUV(max) was evaluated as both a continuous and as a dichotomous variable using a cutoff of
ISSN:1748-717X
1748-717X
DOI:10.1186/1748-717X-9-41